Literature DB >> 19261604

Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.

Xiangdong Zhou1, Yehenew M Agazie.   

Abstract

The Src homology phosphotyrosyl phosphatase 2 (SHP2) plays a positive role in HER2-induced signaling and transformation, but its mechanism of action is poorly understood. Given the significance of HER2 in breast cancer, defining a mechanism for SHP2 in the HER2 signaling pathway is of paramount importance. In the current report we show that SHP2 positively modulates the Ras-extracellular signal-regulated kinase 1 and 2 and the phospoinositide-3-kinase-Akt pathways downstream of HER2 by increasing the half-life the activated form of Ras. This is accomplished by dephosphorylating an autophosphorylation site on HER2 that serves as a docking platform for the SH2 domains of the Ras GTPase-activating protein (RasGAP). The net effect is an increase in the intensity and duration of GTP-Ras levels with the overall impact of enhanced HER2 signaling and cell transformation. In conformity to these findings, the HER2 mutant that lacks the SHP2 target site exhibits an enhanced signaling and cell transformation potential. Therefore, SHP2 promotes HER2-induced signaling and transformation at least in part by dephosphorylating a negative regulatory autophosphorylation site. These results suggest that SHP2 might serve as a therapeutic target against breast cancer and other cancers characterized by HER2 overexpression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19261604      PMCID: PMC2673291          DOI: 10.1074/jbc.M900020200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 2.  The ErbB2 signaling network as a target for breast cancer therapy.

Authors:  Ali Badache; Anthony Gonçalves
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

3.  Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations.

Authors:  M Golam Mohi; Ifor R Williams; Charles R Dearolf; Gordon Chan; Jeffery L Kutok; Sarah Cohen; Kelly Morgan; Christina Boulton; Hirokazu Shigematsu; Heike Keilhack; Koichi Akashi; D Gary Gilliland; Benjamin G Neel
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

4.  Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant.

Authors:  Rebecca Merritt; Michael J Hayman; Yehenew M Agazie
Journal:  Biochim Biophys Acta       Date:  2005-12-20

5.  A role for the scaffolding adapter GAB2 in breast cancer.

Authors:  Mohamed Bentires-Alj; Susana G Gil; Richard Chan; Zhigang C Wang; Yongping Wang; Naoko Imanaka; Lyndsay N Harris; Andrea Richardson; Benjamin G Neel; Haihua Gu
Journal:  Nat Med       Date:  2005-12-20       Impact factor: 53.440

6.  Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation.

Authors:  Y R Hadari; H Kouhara; I Lax; J Schlessinger
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

7.  A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation.

Authors:  T B Deb; L Wong; D S Salomon; G Zhou; J E Dixon; J S Gutkind; S A Thompson; G R Johnson
Journal:  J Biol Chem       Date:  1998-07-03       Impact factor: 5.157

8.  Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.

Authors:  T M Saxton; M Henkemeyer; S Gasca; R Shen; D J Rossi; F Shalaby; G S Feng; T Pawson
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

9.  Somatic PTPN11 mutations in childhood acute myeloid leukaemia.

Authors:  Marco Tartaglia; Simone Martinelli; Ivano Iavarone; Giovanni Cazzaniga; Monica Spinelli; Emanuela Giarin; Valentina Petrangeli; Claudio Carta; Riccardo Masetti; Maurizio Aricò; Franco Locatelli; Giuseppe Basso; Mariella Sorcini; Andrea Pession; Andrea Biondi
Journal:  Br J Haematol       Date:  2005-05       Impact factor: 6.998

10.  The phosphotyrosine phosphatase SHP-2 participates in a multimeric signaling complex and regulates T cell receptor (TCR) coupling to the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T cells.

Authors:  J A Frearson; D R Alexander
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

View more
  26 in total

Review 1.  Targeting protein tyrosine phosphatases for anticancer drug discovery.

Authors:  Latanya M Scott; Harshani R Lawrence; Saïd M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

2.  Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Authors:  Christopher M Furcht; Janine M Buonato; Nicolas Skuli; Lijoy K Mathew; Andrés R Muñoz Rojas; M Celeste Simon; Matthew J Lazzara
Journal:  J Cell Sci       Date:  2014-06-20       Impact factor: 5.285

3.  A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).

Authors:  Zachary Hartman; Werner J Geldenhuys; Yehenew M Agazie
Journal:  J Biol Chem       Date:  2020-02-04       Impact factor: 5.157

4.  Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs.

Authors:  Latanya M Scott; Liwei Chen; Kenyon G Daniel; Wesley H Brooks; Wayne C Guida; Harshani R Lawrence; Said M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Bioorg Med Chem Lett       Date:  2010-12-04       Impact factor: 2.823

5.  Substrate specificity of protein tyrosine phosphatases 1B, RPTPα, SHP-1, and SHP-2.

Authors:  Lige Ren; Xianwen Chen; Rinrada Luechapanichkul; Nicholas G Selner; Tiffany M Meyer; Anne-Sophie Wavreille; Richard Chan; Caterina Iorio; Xiang Zhou; Benjamin G Neel; Dehua Pei
Journal:  Biochemistry       Date:  2011-02-18       Impact factor: 3.162

6.  Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.

Authors:  Liwei Chen; Daniele Pernazza; Latanya M Scott; Harshani R Lawrence; Yuan Ren; Yunting Luo; Xin Wu; Shen-Shu Sung; Wayne C Guida; Said M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

7.  Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer.

Authors:  Jing Jiang; Mei-Shan Jin; Fei Kong; Yin-Ping Wang; Zhi-Fang Jia; Dong-Hui Cao; Hong-Xi Ma; Jian Suo; Xue-Yuan Cao
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

8.  Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer.

Authors:  Simone Muenst; Ellen C Obermann; Feng Gao; Daniel Oertli; Carsten T Viehl; Walter P Weber; Timothy Fleming; William E Gillanders; Savas D Soysal
Journal:  Histopathology       Date:  2013-05-15       Impact factor: 5.087

9.  Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer.

Authors:  B L Allen-Petersen; C J Carter; A M Ohm; M E Reyland
Journal:  Oncogene       Date:  2013-03-11       Impact factor: 9.867

10.  The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.

Authors:  Zachary R Hartman; Michael D Schaller; Yehenew M Agazie
Journal:  Mol Cancer Res       Date:  2013-03-19       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.